Erbitux Addition to Chemotherapy Regimen Can Make Inoperable Disease Operable
Intermittent Androgen Deprivation Therapy Not Equal to Continuous Treatment, Study Finds
Three Organizations Publish Guideline For Biomarker Testing for Targeted Therapies
Avoiding Mediastinal Radiation Can Improve Patient Outcomes
Obese Men With Benign Biopsy At High Risk for Prostate Cancer
Ibrutinib Shows Disease Control In Elderly, High-Risk CLL Patients
Study Finds That CTC Was Used Correctly In Medicare Patients
ASCO Draft Recommendations Define Meaningful Trial Outcomes
Phase II Study Cohort Fails To Overcome Erlotinib Resistance
Alcohol Consumption Does Not Impact Survival of Breast Cancer
Study: Blood Test More Accurate Than Traditional Tumor Biopsy
European Treatment Regimen Less Toxic Than American Method
Study Finds Nearly Two-Thirds Of Children Return to Hospital Following Stem Cell Transplant
NCI CTEP Approved Trials For the Month of April
FDA Breakthrough Designation Granted to Pfizer’s Palbociclib
Trending Stories
- DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated - Banished from the institute he founded, separated from his lab materials, Tom Curran sues Children’s Mercy
Whistleblower lawsuit alleges wrongful firing - Tom Sellers steps down as director of OHSU Knight, replaced by Lisa Coussens
Shivaani Kummar recently named interim CEO - In The Headlines: Private funding can’t replace federal funding—but it can help
- Karen Knudsen tells us why she took the CEO job at the Parker Institute for Cancer Immunotherapy
- Brian Druker, developer of Gleevec, eyes a new feat: Setting the Boston Marathon fundraising record
Current record: $507,000. Proceeds to go to LLS as NIH funding is slashed
